NFL Biosciences (FRA:82F) Debt-to-EBITDA : (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:82F NFL Biosciences SA FRA:82F
26 GF Score
Price €0.69
! 1 Warning Sign
View Full Analysis

What is NFL Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

NFL Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €0.15 Mil. NFL Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €0.43 Mil. NFL Biosciences's annualized EBITDA for the quarter that ended in Dec. 2025 was €-3.37 Mil. NFL Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 was -0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for NFL Biosciences's Debt-to-EBITDA or its related term are showing as below:

FRA:82F' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.31   Med: -0.06   Max: -0.02
Current: -0.16

During the past 6 years, the highest Debt-to-EBITDA Ratio of NFL Biosciences was -0.02. The lowest was -0.31. And the median was -0.06.

FRA:82F's Debt-to-EBITDA is ranked worse than
100% of 304 companies
in the Biotechnology industry
Industry Median: 1.215 vs FRA:82F: -0.16

NFL Biosciences  (FRA:82F) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

NFL Biosciences Debt-to-EBITDA Related Terms

NFL Biosciences Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for NFL Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NFL Biosciences Debt-to-EBITDA Chart

NFL Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial - - - - -

NFL Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

FRA:82F vs VRTX, REGN, MRNA: Debt-to-EBITDA Comparison

For the Biotechnology subindustry, NFL Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NFL Biosciences Debt-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NFL Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where NFL Biosciences's Debt-to-EBITDA falls into.


FRA:82F
26GF Score
NFL Biosciences SA FRA:82F
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NFL Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

NFL Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.147662 + 0.434923) / -3.757153
=-0.16

NFL Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.147662 + 0.434923) / -3.36942
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.

NFL Biosciences Business Description

Other Exchanges ALNFL:France
Address 199 rue Helene Boucher, Castelnau-le-Lez, FRA, 34170
NFL Biosciences SA specializes in the research and development of medicines to combat tobacco addiction that use botanical and pharmaceutical agents. NFL-101 is company's core product, targeting smoking addiction. It is a clinically developed, botanical drug that contains an insignificant amount of nicotine and is composed of well characterized, natural tobacco leaf proteins.
26GF Score

Get the complete analysis for FRA:82F

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price